Home | Regulatory Tracker | KPV
KPV
PCAC recommended
as of October 2026
By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries
As of October 2026, KPV isn’t approved for any use and isn’t on the list of ingredients pharmacies may compound with. It left FDA’s safety-risk list in April 2026 only because its nominators withdrew, and FDA’s page still says the agency has no human exposure data on it. In July 2026, an advisory panel voted 8–6, with one abstention, to recommend adding it. That vote is advice; nothing changes until FDA writes and finalizes a rule. Right now it’s sold mainly by “research use only” sites and some clinics, with no FDA oversight of what’s in the product.
Sources
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (withdrawn table)
U.S. Food & Drug Administration
dated Apr 2026
July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
U.S. Food & Drug Administration
dated Jul 2026
Change log
September 2023
FDA places KPV in Category 2 (significant safety risks).
April 2026
KPV moves to FDA’s “nominated but withdrawn” table after nominators withdraw; FDA’s safety note stays listed.
May 2026
FDA staff briefing recommends against adding KPV to the bulks list.
July 2026
Advisory panel votes 8–6 (1 abstention) to recommend adding KPV, for wound healing and inflammatory conditions.